X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
GLSI-100 (GP2 + GM-CSF) is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with GM-CSF that stimulates an immune response targeting HER2/neu expressing cancers. It is being evaluated for HER2/neu positive breast cancer.
Lead Product(s): GP2 Peptide,GM-CSF
Therapeutic Area: Oncology Product Name: GLSI-100
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
The study demonstrated that GLSI-100, an immunotherapy safely elicited a potent immune response, as evidenced by injection site reactions that correlate to and may serve as a complement to immune response data such as DTH.
Lead Product(s): GP2 Peptide,GM-CSF
Therapeutic Area: Oncology Product Name: GLSI-100
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
With completion of three clinical lots of GP2 for use in Flamingo-01 trial, and in any additional clinical trials run in parallel, Company intends to file additional patent claims surrounding manufacturing of GP2 and the administration of GLSI-100 immunotherapy.
Lead Product(s): GP2 Peptide,GM-CSF
Therapeutic Area: Oncology Product Name: GLSI-100
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
GLSI-100 (GP2 and GM-CSF), immunotherapy to prevent breast cancer Phase III clinical trial critical steps toward study initiation have been completed, including manufacturing, contracting with clinical trial partners, and setting up infrastructure.
Lead Product(s): GP2 Peptide,GM-CSF
Therapeutic Area: Oncology Product Name: GLSI-100
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2022
Details:
GP2 immunotherapy generated GP2-specific immune responses, leading to no metastatic breast cancer recurrence in the HER2/neu 3+ population in the Phase IIb clinical trial, thus supporting GP2’s mechanism of action.
Lead Product(s): GP2 Peptide,GM CSF
Therapeutic Area: Oncology Product Name: GP2
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021
Details:
The broad based immune response suggests the potential for GP2 to treat other HER2/neu 1-3+ expressing cancers. GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy.
Lead Product(s): GP2 Peptide,GM CSF
Therapeutic Area: Oncology Product Name: GP2
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center Phase IIb clinical trial, no recurrences were observed after median 5 years of follow-up.
Lead Product(s): GP2 Peptide,GM CSF
Therapeutic Area: Oncology Product Name: GP2
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
Westport Bio’s coronavirus vaccine program includes up to 7 vaccine candidates which are designed to complement or improve upon the DNA/RNA based coronavirus vaccines that are in advanced Phase III clinical trials or that have recently received EUA from the FDA.
Lead Product(s): GP2 Peptide
Therapeutic Area: Infections and Infectious Diseases Product Name: GP2
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Greenwich LifeSciences
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2020
Details:
The Company’s new manufacturing partner specializes in the current Good Manufacturing Practice (cGMP) of formulating, filling, and labeling drug vials and follows the recent completion of the manufacturing of the GP2 active ingredient.
Lead Product(s): GP2 Peptide,GM-CSF
Therapeutic Area: Oncology Product Name: GP2
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
